Amicus Therapeutics, Inc.
FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, aā¦ read more
Healthcare
Biotechnology
18 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.87
Price-0.34%
-$0.03
1Y
Price
Market Cap
$2.737b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-3.7%
EBITDA Margin-15.8%
Net Profit Margin-18.7%
Free Cash Flow MarginRevenue
$571.160m
+8.1%
1y CAGR+20.6%
3y CAGR+17.4%
5y CAGREarnings
-$38.096m
+32.1%
1y CAGR+43.7%
3y CAGR+34.1%
5y CAGREPS
-$0.12
+33.3%
1y CAGR+45.3%
3y CAGR+36.7%
5y CAGRBook Value
$204.304m
$815.303m
Assets$610.999m
Liabilities$443.315m
DebtDebt to Assets
54.4%
13.4x
Debt to EBITDAFree Cash Flow
-$48.914m
-30.6%
1y CAGR+25.2%
3y CAGR+23.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company